Literature DB >> 25937339

Activity of botulinum neurotoxin type D (strain 1873) in human neurons.

Sabine Pellett1, William H Tepp2, Jacob M Scherf2, Christina L Pier2, Eric A Johnson2.   

Abstract

Botulinum Neurotoxin type D (BoNT/D) causes periodic outbreaks of botulism in cattle and horses, but is rarely associated with human botulism. Previous studies have shown that humans responded poorly to peripheral injection of up to 10U of BoNT/D. Isolated human pyramidalis muscle preparations were resistant to BoNT/D, whereas isolated human intercostal muscle preparations responded to BoNT/D similarly as to other BoNT serotypes. In vitro data indicate that BoNT/D does not cleave human VAMP1 efficiently, and differential expression of the VAMP 1 and 2 isoforms may be responsible for the above observations. Here we examined sensitivity of cultured human neurons derived from human induced pluripotent stem cells to BoNT/D. Our data indicate that BoNT/D can enter and cleave VAMP 2 in human neurons, but at significantly lower efficiency than other BoNT serotypes. In addition, BoNT/D had a short duration of action in the cultured neurons, similar to that of BoNT/E. In vivo analyses indicated a slower time to death in mice, as well as a later onset and shorter duration of action than BoNT/A1. Finally, examination of BoNT/D activity in various rodent and human cell models resulted in dramatic differences in sensitivity, indicating a unique cell entry mechanism of BoNT/D.
Copyright © 2015 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  BoNT/D; Botulinum neurotoxin; Botulinum neurotoxin D; Clostridium botulinum type D

Mesh:

Substances:

Year:  2015        PMID: 25937339      PMCID: PMC4458207          DOI: 10.1016/j.toxicon.2015.04.015

Source DB:  PubMed          Journal:  Toxicon        ISSN: 0041-0101            Impact factor:   3.033


  38 in total

Review 1.  Infectious agents of bioterrorism: a review for emergency physicians.

Authors:  Nicholas E Kman; Richard N Nelson
Journal:  Emerg Med Clin North Am       Date:  2008-05       Impact factor: 2.264

2.  Axonal transport and distribution of synaptobrevin I and II in the rat peripheral nervous system.

Authors:  J Y Li; L Edelmann; R Jahn; A Dahlström
Journal:  J Neurosci       Date:  1996-01       Impact factor: 6.167

Review 3.  Intracellular targets and metalloprotease activity of tetanus and botulism neurotoxins.

Authors:  G Schiavo; O Rossetto; F Tonello; C Montecucco
Journal:  Curr Top Microbiol Immunol       Date:  1995       Impact factor: 4.291

Review 4.  The typing of botulinal neurotoxins.

Authors:  D F Giménez; J A Giménez
Journal:  Int J Food Microbiol       Date:  1995-09       Impact factor: 5.277

5.  In vitro characterization of botulinum toxin types A, C and D action on human tissues: combined electrophysiologic, pharmacologic and molecular biologic approaches.

Authors:  J A Coffield; N Bakry; R D Zhang; J Carlson; L G Gomella; L L Simpson
Journal:  J Pharmacol Exp Ther       Date:  1997-03       Impact factor: 4.030

6.  Botulinum neurotoxin serotype D attacks neurons via two carbohydrate-binding sites in a ganglioside-dependent manner.

Authors:  Jasmin Strotmeier; Kwangkook Lee; Anne K Völker; Stefan Mahrhold; Yinong Zong; Johannes Zeiser; Jie Zhou; Andreas Pich; Hans Bigalke; Thomas Binz; Andreas Rummel; Rongsheng Jin
Journal:  Biochem J       Date:  2010-10-15       Impact factor: 3.857

Review 7.  Clostridium botulinum in cattle and dairy products.

Authors:  Miia Lindström; Jan Myllykoski; Seppo Sivelä; Hannu Korkeala
Journal:  Crit Rev Food Sci Nutr       Date:  2010-04       Impact factor: 11.176

8.  Differential expression of synaptic vesicle protein 2 (SV2) isoforms.

Authors:  S M Bajjalieh; G D Frantz; J M Weimann; S K McConnell; R H Scheller
Journal:  J Neurosci       Date:  1994-09       Impact factor: 6.167

9.  Comparison of the primary rat spinal cord cell (RSC) assay and the mouse bioassay for botulinum neurotoxin type A potency determination.

Authors:  Sabine Pellett; William H Tepp; Stephen I Toth; Eric A Johnson
Journal:  J Pharmacol Toxicol Methods       Date:  2010-01-25       Impact factor: 1.950

10.  Botulinum neurotoxin D uses synaptic vesicle protein SV2 and gangliosides as receptors.

Authors:  Lisheng Peng; William H Tepp; Eric A Johnson; Min Dong
Journal:  PLoS Pathog       Date:  2011-03-31       Impact factor: 6.823

View more
  12 in total

Review 1.  Botulinum Neurotoxins: Biology, Pharmacology, and Toxicology.

Authors:  Marco Pirazzini; Ornella Rossetto; Roberto Eleopra; Cesare Montecucco
Journal:  Pharmacol Rev       Date:  2017-04       Impact factor: 25.468

2.  Substrate cleavage and duration of action of botulinum neurotoxin type FA ("H, HA").

Authors:  Sabine Pellett; William H Tepp; Guangyun Lin; Eric A Johnson
Journal:  Toxicon       Date:  2017-12-19       Impact factor: 3.033

3.  Botulinum toxin type D blocks autonomic cholinergic synapses in humans: discussion of a potential therapeutic use.

Authors:  Dirk Dressler; Katja Kollewe; Tilmann H C Kruger; Niklas Gade; Stefan Sikorra; Hans Bigalke
Journal:  J Neural Transm (Vienna)       Date:  2019-06-15       Impact factor: 3.575

4.  Novel Native and Engineered Botulinum Neurotoxins.

Authors:  Lance Steward; Mitchell F Brin; Amy Brideau-Andersen
Journal:  Handb Exp Pharmacol       Date:  2021

5.  Botulinum neurotoxins A, B, C, E, and F preferentially enter cultured human motor neurons compared to other cultured human neuronal populations.

Authors:  Sabine Pellett; William H Tepp; Eric A Johnson
Journal:  FEBS Lett       Date:  2019-07-04       Impact factor: 4.124

Review 6.  Current status and future directions of botulinum neurotoxins for targeting pain processing.

Authors:  Sabine Pellett; Tony L Yaksh; Roshni Ramachandran
Journal:  Toxins (Basel)       Date:  2015-11-04       Impact factor: 4.546

Review 7.  Critical Analysis of Neuronal Cell and the Mouse Bioassay for Detection of Botulinum Neurotoxins.

Authors:  Sabine Pellett; William H Tepp; Eric A Johnson
Journal:  Toxins (Basel)       Date:  2019-12-07       Impact factor: 4.546

8.  The Light Chain Defines the Duration of Action of Botulinum Toxin Serotype A Subtypes.

Authors:  Sabine Pellett; Marite Bradshaw; William H Tepp; Christina L Pier; Regina C M Whitemarsh; Chen Chen; Joseph T Barbieri; Eric A Johnson
Journal:  MBio       Date:  2018-03-27       Impact factor: 7.867

Review 9.  Novel Botulinum Neurotoxins: Exploring Underneath the Iceberg Tip.

Authors:  Domenico Azarnia Tehran; Marco Pirazzini
Journal:  Toxins (Basel)       Date:  2018-05-10       Impact factor: 4.546

Review 10.  Light Chain Diversity among the Botulinum Neurotoxins.

Authors:  Alexander P Gardner; Joseph T Barbieri
Journal:  Toxins (Basel)       Date:  2018-07-02       Impact factor: 4.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.